MRNA:OTCQB-Marina Biotech Inc (USD)

COMMON STOCK | Biotechnology | OTCQB - U.S. Registered

Last Closing

USD 30.93

Change

-0.94 (-2.95)%

Market Cap

USD 0.02B

Volume

0.01B

Analyst Target

USD 89.73
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Marina Biotech Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-2.02 (-0.44%)

USD 118.90B
REGN Regeneron Pharmaceuticals Inc

-1.60 (-0.24%)

USD 73.95B
ARGX argenx NV ADR

+13.07 (+2.05%)

USD 40.41B
ALNY Alnylam Pharmaceuticals Inc

-3.03 (-1.13%)

USD 34.99B
ONC BeiGene, Ltd.

+2.09 (+0.94%)

USD 25.62B
RPRX Royalty Pharma Plc

+0.09 (+0.28%)

USD 18.12B
SMMT Summit Therapeutics PLC

+0.49 (+2.57%)

USD 17.52B
UTHR United Therapeutics Corporatio..

+17.43 (+4.93%)

USD 15.68B
INCY Incyte Corporation

+2.72 (+4.10%)

USD 14.29B
INSM Insmed Inc

-0.29 (-0.36%)

USD 13.70B

ETFs Containing MRNA

MRN3:LSE Leverage Shares 3x Long M.. 300.17 % 0.00 %

N/A

USD 0.80M
MSGR 6.26 % 0.00 %

N/A

N/A
CURE:XETRA 5.70 % 0.00 %

N/A

N/A
HVAX:CA 4.95 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 4.67 % 0.00 %

+0.03 (+-0.81%)

N/A
CURG:LSE VanEck Genomics and Healt.. 4.20 % 0.00 %

-0.13 (-0.81%)

USD 5.28M
XDNA:CA iShares Genomics Immunolo.. 4.10 % 0.00 %

-0.53 (-0.81%)

CAD 5.10M
LS:CA 3.47 % 2.21 %

N/A

N/A
XNNV:XETRA 3.03 % 0.00 %

N/A

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

-0.24 (-0.81%)

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

-0.34 (-0.81%)

N/A
ASRP:XETRA 2.69 % 0.00 %

N/A

N/A
FCTR First Trust Lunt U.S. Fac.. 1.68 % 0.00 %

-0.08 (-0.81%)

N/A
IBBQ Invesco Nasdaq Biotechnol.. 1.60 % 0.00 %

+0.34 (+-0.81%)

USD 0.04B
TAEQ 1.46 % 0.00 %

N/A

N/A
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

-0.03 (-0.81%)

USD 3.86B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+1.40 (+-0.81%)

N/A
FLAG 0.00 % 1.52 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.01 (+-0.81%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
RYH 0.00 % 0.40 %

N/A

N/A
XT iShares Exponential Techn.. 0.00 % 0.47 %

+0.20 (+-0.81%)

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
MRNS:LSE -299.96 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.61% 20% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.61% 20% F 11% F
Trailing 12 Months  
Capital Gain -63.77% 29% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -63.77% 29% F 12% F
Trailing 5 Years  
Capital Gain 62.40% 86% B+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.40% 86% B+ 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 54.99% 79% B- 88% B+
Dividend Return 54.99% 79% B- 88% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 171.97% 26% F 14% F
Risk Adjusted Return 31.98% 86% B+ 63% D
Market Capitalization 0.02B 98% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector